Materials and
Methods:
The animal studies were approved by the local animal ethics committee. Perfluorocarbon (PFC) emulsions were injected intravenously in a mouse model of atherosclerosis (n = 13), after which 19 F and anatomic MR imaging were performed at the level of the thoracic aorta and its branches at 9.4 T. Four of these animals were imaged repeatedly (at 2-14 days) to determine the optimal detection time. Repeated-measures analysis of variance with a Tukey test was applied to determine if there was a significant change in 19 F signal-to-noise ratio (SNR) of the plaques and liver between the time points. Six animals were injected with a PFC emulsion that also contained a fluorophore. As a control against false-positive results, wild-type mice (n = 3) were injected with a PFC emulsion, and atherosclerotic mice were injected with a saline solution (n = 2). The animals were sacrificed after the last MR imaging examination, after which high-spatial-resolution ex vivo MR imaging and bright-field and immunofluorescent histologic examination were performed.
Results:
19 F MR signal was detected in vivo in plaques in the aortic arch and its branches. The SNR was found to significantly increase up to day 6 (P , .001), and the SNR of all mice at this time point was 13.4 6 3.3. The presence of PFC and plaque in the excised vessels was then confirmed both through ex vivo 19 F MR imaging and histologic examination, while no signal was detected in the control animals. Immunofluorescent histologic findings confirmed the presence of PFC in plaque macrophages.
Conclusion:
19 F MR imaging allows the noninvasive in vivo detection of inflammation in atherosclerotic plaques in a mouse model of atherosclerosis and opens up new avenues for both the early detection of vulnerable atherosclerosis and the elucidation of inflammation mechanisms in atherosclerosis.
I n recent years, it has become evident that anatomic predictors, including high plaque burden and the presence of a thin fibrous cap, are by themselves not sufficiently specific to allow prediction of which atherosclerotic plaques will rupture and lead to future events (1) . A highly promising and complementary strategy for the identification and definition of plaque vulnerability is the direct visualization of inflammation (2) . Indeed, the role of inflammation at all stages of atherosclerosis is now well established (2) , and the presence of a macrophage-rich inflammation has been linked to plaque vulnerability (3) .
Fluorine 18 ( 18 F) fluorodeoxyglucose positron emission tomography (PET) can, for example, be used for the noninvasive and highly sensitive imaging of inflammation in atherosclerosis through the uptake of the tracer 18 F fluorodeoxyglucose in a plaque (4) . However, the tracer requires a cyclotron for production, and its radioactivity renders the technique less suitable for long-term disease monitoring. Magnetic resonance (MR) imaging, in combination with the intravenous injection of a contrast agent that is phagocytized by circulating immune cells, can also be used for imaging inflammation in atherosclerosis: Several types of custom-designed gadolinium-and iron oxide-based contrast agents that target inflammation have been described
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(5-7) and used for plaque characterization. Iron oxide particles have, for example, been used in humans to detect inflammation in carotid plaques (8) and in the myocardium after infarction (9) . However, these techniques have the disadvantage of not being quantitative or being custom designed, or they will likely remain limited to animal studies because of marked regulatory hurdles or concerns related to toxicity and safety. Therefore, despite their promise, a translation to human studies still appears to be distant.
In this proof-of-principle study, we instead propose to use fluorine 19 ( 19 F) MR imaging of injected perfluorocarbons (PFCs) (10, 11) for the visualization and quantitative characterization of inflammation in atherosclerotic plaque in vivo. PFCs are inert, nontoxic carbohydrates in which all hydrogen has been replaced with fluorine and of which several types have passed through U.S. Food and Drug Administration trials (12) as blood volume expanders. 19 F MR imaging has several distinct advantages over conventional hydrogen 1 ( 1 H) molecular imaging, which stem from the combination of the facts that the fluorine atoms in the PFCs are imaged directly (in lieu of their effect on their surroundings) and that fluorine is not naturally abundant in the human body at a concentration that is detectable with MR imaging. The 19 F signal is therefore highly specific to the injected PFC, and the signal strength is linked to its local quantity, which allows the fluorine concentration to be directly quantified. This means not only that selective angiography with high image contrast (13) can be performed immediately after injection, but also that inflammation in various disease processes such as myocardial infarction (14) , arthritis (15) , and myocarditis (16) can be visualized with high specificity, as evidenced in various mouse models. Furthermore, post mortem proof-of-principle studies have shown that plaques in the human carotid artery can be labeled and that the PFC nanoparticle concentration can be quantified on a nanomolar scale (17 
Materials and Methods

Animal Protocol
The animal studies were approved by the local animal ethics committee. , WT = WT control) followed a high-fat diet, 12 weeks after which they were serially injected with PFC, FITC PFC, or saline. They then underwent serial MR imaging or a single session of MR imaging 6 days after the last injection. Immediately after the last MR imaging session they were euthanized, which was followed by ex vivo MR imaging and histologic examination. Immunofluorescent histologic examination (Immunofluo) was then performed on the aortas of the FITC PFC-injected mice.
All MR experiments were performed in a 9.4-T horizontal bore animal spectrometer (Varian, Palo Alto, Calif). Animals underwent isoflurane anesthesia (4% in air for induction, followed by 2% in a mixture of 60% oxygen and 40% air). Electrocardiographic electrodes were applied to the paws, and the animals were placed in a dedicated holder on top of a respiration pillow and a custom-designed 18-mm-diameter quadrature surface coil that is tunable to both the . Signalto-noise ratio (SNR) levels were established for several regions to gain insight into the time course of signal change and the maximal signal strength that could be obtained with the technique (not to quantify concentrations).The SNR of a region of interest was defined as the average signal in the region of interest divided by the standard deviation of a 10 3 5-mm 2 region of noise outside possible for the control mice (Fig 1) . ApoE 2/2 mice were selected, since this is a well-established model for atherosclerosis research and since the size of their aortas is on the same order of magnitude as that of human coronary arteries. A PFC emulsion based on 10% wt/vol perfluoro-15-crown-5 ether was prepared in-house as described previously (14) . The emulsion contains nanoparticles with a mean size of 130 nm, produces a single spectral line at 292.8 ppm (18), and contains approximately 8 3 10 9 19 F atoms per nanoparticle. A PFC injection scheme that was estimated to maximize the PFC loading in the plaque at the time of MR imaging was experimentally developed: Every 3 days during weeks 10-12 after the start of the diet, seven ApoE 2/2 mice and the three WT mice received 100-mL tailvein injections. The rationale for these empirically chosen small injections was to inject a small but still substantial volume with a sufficiently large time interval to allow the body to accommodate for the increase in blood volume. After the 12 weeks, the animals received a large PFC injection of 500 mL. Six more ApoE 2/2 mice received the same injection protocol with fluorescein isothiocyanate (FITC) PFC (15) , an emulsion to which the fluorophore FITC was added to perform histologic validation with fluorescence microscopy. Two control ApoE 2/2 mice were injected with saline to characterize the 19 F signal that does not originate from the injected PFCthat is, the anesthetic isoflurane (which is known to be absorbed in the subcutaneous fat [19] ).
In Vivo MR Imaging First, MR images were obtained in four PFC-injected ApoE 2/2 mice on day 2, 4, 6, 8, and 14 after the last injection to determine the optimal time delay between injection and imaging, since the specific pharmacokinetics of this PFC in atherosclerotic plaque are unknown. The remaining three PFC-injected animals, as well as the six FITC PFC-injected animals, the two saline-injected ApoE 2/2 mice, and the three WT controls underwent imaging 6 days after the last injection. 
In the mice that underwent imaging on multiple days, the 19 F SNR of the aortic arch and its branches, as well as that of the liver, were compared between the different days to determine the optimal time point after which the SNR no longer increases significantly in the aortic arch and its branches. 
Ex Vivo Imaging
(64 3 64 3 32 matrix; resolution, 0.31 3 0.23 3 0.31 mm 3 or 22.9 nL; 640 signals averaged; 40/1.5; acquisition time, 14.5 hours) gradient-echo pulse sequences at the same anatomic location were used. Both data sets were then interpolated to a 512 3 512 3 256 matrix size, semiautomatically segmented, and fused in Matlab (Mathworks).
Histologic Examination
For two mice in each group, the aortic arches and branching vessels were embedded in paraffin, and 3-mm-thick sections were obtained at the level of plaques in the brachiocephalic artery. Movat pentachrome staining (20) Immunofluorescent staining was performed (by C.G., with 9 years of experience with immunohistochemistry) in adjacent sections to confirm the presence of FITC PFC in macrophages. Sections were selectively immunostained for mouse macrophages with antimouse Mac-2 antibody (rat monoclonal antibody, Cedarlane, Burlington, Canada). The FITC signal was amplified by using an anti-FITC antibody (rabbit polyclonal antibody; Invitrogen, Grand Island, NY) to avoid nonspecific autofluorescence contamination. Mac-2 and FITC were visualized with Alexa 594 and Alexa 488 conjugated antibodies (Molecular Probes, Eugene, Oregon), respectively. Nuclei were stained with 4',6-diamidino-2-phenylindole (Molecular Probes). Imaging was performed by using an Axiovision fluorescence microscope (Carl Zeiss, Oberkochen, Germany). (21), such as the aortic arch, the carotid arteries, and the brachiocephalic artery (Fig 2, A, B) . Signal was also observed in subcutaneous fat, but control experiments with ApoE 2/2 mice that were injected with saline instead of PFC confirmed that this was isoflurane, which accumulates exclusively in subcutaneous fat (19) . No 19 F signal was observed in the descending thoracic aorta of any of the mice. PFC-injected WT control mice showed no 19 F signal at the level of the aorta or its branches. However, signal was observed in the liver, lymph nodes, and subcutaneous fat, as expected. 19 F MR images of the PFC-injected ApoE 2/2 mice that underwent imaging multiple times demonstrated that the 19 F SNR in the aorta and its branches no longer significantly increases after day 6, when a 117% SNR enhancement (P , .001) versus that of day 2 was observed (Fig 2, C) . Day 6 after PFC injection was therefore deemed the optimal imaging day for the protocol. The mean 19 F SNR of all PFC-injected ApoE 2/2 mice on day 6 was 13.4 6 3.3 (range, 9.3-17.6) in the aortic arch and its branches, while the highest SNR (117 6 22) was found in the liver on day 8 (P = .005, Fig 2, D) .
Statistical Analyses
Ex Vivo Confirmation of PFC in Plaque
Plaques that were identified on the photographs (Fig 3, A) were also individually identified on the ex vivo MR images (Fig 3, B) , which confirmed that the EXPERIMENTAL STUDIES: Fluorine MR Imaging of Inflammation in Atherosclerotic Plaque in Vivo van Heeswijk et al F SNR in the plaques of the group of mice that underwent imaging multiple times demonstrates that the SNR does not significantly change after day 6. D, Plot of 19 F SNR in the liver shows a similar trend as that in the plaques, albeit with a higher SNR. The SNR was not significantly different among consecutive days, and only the increase from day 2 to day 6 was statistically significant in the liver when all days were compared. PCE = perfluoro-15-crown-5 ether.
source of the 19 F signal was within the aortas. Three-dimensional visualizations of segmented high-spatial-resolution 3D MR imaging further illustrated the location of the PFC deposits in the vessel wall (Fig 3, C) .
Co-localization of PFC and Immune Cells
Movat pentachrome staining confirmed the presence of intermediate plaques at the locations of the 19 F signal, consistent with the disease model (Fig 4, A, B) . Subsequent immunofluorescent staining for mouse macrophages (through Mac-2) and PFC (through FITC) demonstrated the presence of PFC in plaque macrophages through the colocalization of the fluorescent signals, although not all PFC was contained in macrophages (Fig 4, C-E) . Importantly, immunofluorescent staining showed no macrophage or 19 F signal in the WT control mice, while in the control ApoE 2/2 mice that were injected with saline-that is, those without PFConly a macrophage signal was detected at histologic examination.
Discussion
This study demonstrated the feasibility of the in vivo 19 F MR imaging detection of inflammation in atherosclerotic plaque, with ex vivo imaging and immunofluorescent histologic findings as the reference standard. The technique differs from previously described MR imaging techniques in that the PFC does not indirectly modulate an existing signal like iron oxide (22) or gadolinium (23) nanoparticles do but directly generates the 19 F signal itself without the presence of background signals. This allows for very high specificity and the ultimate possibility of direct SNR quantification that is linearly related to the present quantity of PFC (17) . Since there is no need for potentially harmful ionizing radiation, and since the PFC particles are considered safe (several variants have been studied in clinical trials) (24), 19 F MR imaging appears to be well positioned for translation into the clinical setting, where it may be used to monitor the response of an individual patient to a therapy designed to decelerate, halt, or reverse plaque progression.
Our study had limitations. The PFC concentration itself was not quantified in this study, since the effects of motion compensation through averaging on the signal strength has not been studied and since the loading of the used surface radiofrequency coil would need to be determined for each mouse individually (25) . A minimum amount of labeled immune cells that are needed for the signal to be detected is therefore difficult to establish, although a detection limit of this type of imaging protocol was previously reported to be approximately 400 cells per voxel (14) . Considering that no 19 F signal was detected in the descending aorta and that smaller plaques commonly occur there (26) , an improved sensitivity might be needed to detect very small plaque formations. Fortunately, several avenues are available for future improvements, such as an optimized PFC administration scheme; a higher PFC load in the emulsion (safe formulations with up to 30% instead of the 10% used here have been reported [27] ); the implementation of novel image reconstruction methods, such as compressed sensing (28) ; or the postformulation addition of a targeting ligand (29) . Furthermore, the exact correlation of the 19 F MR signal with the macrophage load as can be determined through histologic examination should be established, while the exact populations that internalize PFC could be investigated by means of flow cytometry.
EXPERIMENTAL STUDIES:
We found that 6 days after the last injection was the optimal time point to perform imaging. This time point most likely results from a combination of both the number and spread of the injection series and the composition and clearance rate of the PFC emulsion. However, we did not further optimize the injection scheme for this proof-ofprinciple study. Possible sources of the increase in PFC over time are the liver and spleen, where the sequestered immune cells retain PFC for several weeks (30) . The slow increase and decrease of 19 F signal over time in the liver is furthermore consistent with previous observations for perfluoro-15-crown-5 ether (30) .
Immunofluorescent histologic results further demonstrated PFC absorption by cell types other than macrophages, which is in line with the findings of other studies (16, 31) . However, since the FITC is covalently linked only to the phospholipids in the emulsion and not to the perfluoro-15-crown-5 ether, it should be noted that we cannot be certain that these two components of the FITC PFC are still 100% associated with one another, especially at the later imaging time points. Furthermore, contrary to nanoparticles that exhibit a certain targeting ligand, it currently remains to be elucidated how exactly the "passive" nanoparticles used in this study , 363) demonstrates that most of the PFC is contained within the macrophages (solid arrows on C-E ). Cells that are not macrophages that absorbed PFC (arrowheads on C and E ) and cells that are not macrophages and did not absorb PFC (dotted arrows on C and E ) can also be observed. migrate into the plaque. They might be phagocytized by monocytes in the bloodstream that then migrate to the plaque, or they might diffuse through leaky endothelium via the vasa vasorum or directly into the plaque or by a combination of the above. Should a higher sensitivity be obtained by using advanced methods, such mechanisms could be studied in-depth by following the fate of injected specific immune cell populations that are labeled in vitro (32) , which would result in valuable new insights into the mechanisms of cell turnover in atherosclerosis.
In the clinical realm, the most established noninvasive atherosclerosis inflammation imaging technique is currently PET of the injected radioactive tracer 18 F fluorodeoxyglucose, which is used to detect an increase in plaque metabolism and has a very high sensitivity, while it also has the advantage of being quantifiable (33) . However, the spatial resolution of PET is inherently quite low, it requires a nearby cyclotron, and, to provide an anatomic reference for such small structures as atherosclerotic plaques, it needs to be overlaid on an anatomic computed tomographic (CT) or MR image. CT involves another dose of potentially harmful ionizing radiation and renders the technique less suitable for monitoring disease progression or therapy, while for the 19 F MR imaging technique described here, anatomic 1 H images are readily available for coregistration.
Given that 0.5 L of PFC has already been injected as a blood volume expander in humans (12) , the dosage in this study was deliberately chosen to be high to maximize the 19 F signal and to ensure visualization of the plaque inflammation. However, a dose optimization or a study of the absorption kinetics has not yet been performed, and it can therefore be hypothesized that fewer (perhaps even a single) or smaller injections may achieve similar plaque 19 F loading. It should also be noted that because of the slow clearance kinetics of the crown ether used in this study (30) , other PFCs might be more suitable for human applications. PFCs with a single resonance, such as perfluoropolyether (34) or "Perfecta" (35) , might have different kinetics and allow for fewer injections, although this remains to be tested. Furthermore, given that the voxel size in humans is often more than two orders of magnitude larger than that used in EXPERIMENTAL STUDIES: Fluorine MR Imaging of Inflammation in Atherosclerotic Plaque in Vivo van Heeswijk et al mice here (up to 2 3 2 3 8 mm 3 or 32 mL vs 0.22 mL used in this study), a smaller dose may in fact be sufficient for initial plaque macrophage visualization in human carotid arteries. A quick calculation suggests that scaling from 2.5 mL total blood volume in mice to 5 L in humans with 10 times larger voxel size results in a 100-mL slow infusion volume (while the smaller injections translate to 20 mL), but this remains to be investigated and optimized. Since the detection limit of 19 F is on the order of 400 mmol/L for gradient-echo MR imaging (13), a detection limit down to at least 13 nmol per voxel might be expected in humans. This relative signal increase could equally be used to improve the sensitivity and to reduce the 19 F MR imaging time. In conclusion, we provided a preliminary account of the utility of a safe fluorine MR imaging technique for the in vivo visualization of inflammation in atherosclerosis. This opens a new avenue for research and discovery in atherosclerosis on the one hand and may ultimately provide a tool to better help guide and monitor therapy in patients at risk for atherosclerosis or those with documented atherosclerosis on the other hand.
